Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

Individuals diagnosed with myasthenia gravis as well as caregivers ... and funds critical research that could lead to improved diagnosis times, and an overall improved quality of life through ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit relapses, but evidence suggests social resources may be not applied to this ...